Gossamer Bio/$GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Ticker
$GOSS
Sector
Primary listing
Employees
162
Headquarters
Website
Gossamer Bio Metrics
BasicAdvanced
$77M
-
-$0.75
2.11
-
Price and volume
Market cap
$77M
Beta
2.11
52-week high
$3.87
52-week low
$0.32
Average daily volume
18M
Financial strength
Current ratio
2.643
Quick ratio
2.356
Long term debt to equity
-164.523
Total debt to equity
-165.287
Interest coverage (TTM)
-14.86%
Profitability
EBITDA (TTM)
-163.229
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-351.49%
Operating margin (TTM)
-336.81%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-41.86%
Return on equity (TTM)
365.33%
Valuation
Price to revenue (TTM)
1.554
Price to book
-0.63
Price to tangible book (TTM)
-0.63
Price to free cash flow (TTM)
-0.44
Free cash flow yield (TTM)
-227.42%
Free cash flow per share (TTM)
-0.75
Growth
Revenue change (TTM)
-57.74%
Earnings per share change (TTM)
198.37%
3-year earnings per share growth (CAGR)
-34.98%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
Business Wire·20 hours ago
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
Business Wire·24 hours ago
GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
Newsfile Corp·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $77M as of April 08, 2026.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of April 08, 2026.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of April 08, 2026.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 2.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.